ADCs loaded with a topoisomerase I inhibitor, such as T-Dxd and SG, increase tumor-infiltrating DCs and CD8+ T cells, and stimulate the expression of PD-L1 and MHC class I upon tumor cells. Here, CD274 is linked to neoplasm.